August 4, 2022
Mitsubishi Tanabe Pharma said on August 3 that the company’s April-June revenue grew 2.9% year on year thanks to solid performances from its core products in Japan, with the Crohn’s disease treatment Stelara (ustekinumab) enjoying a big leap. In the...read more